RecruitingNCT07363252
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients - REMAIN Study
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Enrollment
100 participants
Start Date
Apr 14, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Age ≥ 18 years
- Diagnosis of radically resected IB-IIIA NSCLC with EGFR activating mutation
- Treatment with adjuvant osimertinib (starting from September 2022, date of approval) according to clinical practice
- Recurrence of disease during or after adjuvant therapy with osimertinib received according to clinical practice
- Availability of tissue and/or liquid biopsy sample collected at the time of recurrence
- Signed informed consent.
Exclusion Criteria3
- Unavailability of tissue and/or liquid biopsy sample collected at the time of recurrence
- Concomitant synchronous malignancies aside from NSCLC or any concurrent and/or active malignancy that has required treatment within 2 years
- Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOsimertinib
Characterization of the molecular mechanisms of recurrence to adjuvant osimertinib
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07363252